Cubist Systematic Strategies LLC Acquires 8,358 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Cubist Systematic Strategies LLC raised its holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 53.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,120 shares of the company’s stock after buying an additional 8,358 shares during the period. Cubist Systematic Strategies LLC owned about 0.06% of Vigil Neuroscience worth $41,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in VIGL. abrdn plc raised its holdings in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after purchasing an additional 293,461 shares during the last quarter. Blair William & Co. IL purchased a new stake in Vigil Neuroscience during the fourth quarter worth about $551,000. Renaissance Technologies LLC increased its holdings in Vigil Neuroscience by 698.5% during the fourth quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock worth $624,000 after buying an additional 321,300 shares during the last quarter. Barclays PLC increased its holdings in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after buying an additional 19,436 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Vigil Neuroscience by 85.3% during the fourth quarter. Marshall Wace LLP now owns 266,895 shares of the company’s stock worth $454,000 after purchasing an additional 122,853 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Stock Performance

VIGL stock opened at $2.49 on Tuesday. The company has a market capitalization of $116.21 million, a PE ratio of -1.21 and a beta of 1.90. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $6.06. The company’s 50 day moving average price is $1.94 and its two-hundred day moving average price is $2.24.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, research analysts predict that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. William Blair upgraded shares of Vigil Neuroscience to a “strong-buy” rating in a research report on Thursday, April 24th. Wedbush restated an “outperform” rating and issued a $13.00 price objective on shares of Vigil Neuroscience in a research report on Monday, May 5th. Finally, HC Wainwright dropped their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 14th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.